TP53 and lymphoma: In this report, we show that MDM2/MDM4 overexpression contributes to the phenotype of RRCLs and MMRi36 can target MDM2/MDM4/XIAP for degradation leading to p53-independent apoptosis in p53-mutant lymphoma cells and non-apoptotic anti-lymphoma effect in RRCLs.